Dec 3 (Reuters) - The U.S. Food and Drug Administration added a new black-box warning, its harshest, to the label of Pfizer Inc"s (PFE.N) arthritis drug, Xeljanz, citing increased risk of major cardiac-related problems in some patients, the drugmaker said on Friday.
مشاركة :